Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Riverwater Partners Small Cap Strategy Nathan Fredrick, CFA | “AtriCure ($ATRC) specializes in surgical devices for cardiac ablation and left atrial appendage management to treat atrial fibrillation and post-operative pain, representing an average weight of 3.88% during the quarter. The manager maintains an enthusiastic bullish stance following a quarter in which shares roughly doubled, driven by expanding free cash flows, consistent core operational execution, and broader market rotation back into profitable med-tech innovators. The investment rationale rests on strong economic moats created by specialized regulatory approvals, surgeon workflow entrenchment, and expanding addressable markets. The company has exhibited operating leverage and steady cash generation, improving free cash flow every quarter since initial purchase, and trades at a noticeable valuation discount relative to large-cap medical device peers. Key growth catalysts include ongoing market share gains in core cardiac ablation, commercial scaling of its pain management division, and index inclusion in the S&P SmallCap 600. Primary downside risks center around emerging competitive entrants targeting left atrial appendage management and broader med-tech multiple contractions.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.